Dendreon's (DNDN) Provenge Sales May be Slumping...
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Join SI Premium – FREE
Dendreon (Nasdaq: DNDN) could be headed lower today following reports that its prostate-cancer treatment Provenge might not be selling well.
The WSJ noted today that Dendreon's go-to product has been met with lagging sales amid increasing competition from medicines that are easier to administer as well as doctors' skepticism about the product's efficacy.
Provenge works by drawing cells out of a patients blood, processing them outside the body, and then infusing the cells back in to jumpstart the patient's own immune system against prostate tumors.
Shares are flat on the session Friday.
The WSJ noted today that Dendreon's go-to product has been met with lagging sales amid increasing competition from medicines that are easier to administer as well as doctors' skepticism about the product's efficacy.
Provenge works by drawing cells out of a patients blood, processing them outside the body, and then infusing the cells back in to jumpstart the patient's own immune system against prostate tumors.
Shares are flat on the session Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Omeros stock tumbles after EU panel rejects Yartemlea
- Roku to spend $25M on child privacy features in Florida settlement
- Iran's Nournews: sound of explosion heard in Iran's Sirik
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
